Skip to main content
Journal cover image

Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.

Publication ,  Journal Article
Cochrane, AB; Lyster, H; Lindenfeld, J; Doligalski, C; Baran, D; Yost, C; Shullo, M; Schweiger, M; Weill, D; Stuckey, L; Ivulich, S; Scheel, J ...
Published in: J Heart Lung Transplant
October 2020

In 2009, the International Society for Heart and Lung Transplantation recognized the importance and challenges surrounding generic drug immunosuppression. As experience with generics has expanded and comfort has increased, substantial issues have arisen since that time with other aspects of immunomodulation that have not been addressed, such as access to medicines, alternative immunosuppression formulations, additional generics, implications on therapeutic drug monitoring, and implications for special populations such as pediatrics and older adults. The aim of this consensus document is to address critically each of these concerns, expand on the challenges and barriers, and provide therapeutic considerations for practitioners who manage patients who need to undergo or have undergone cardiothoracic transplantation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Heart Lung Transplant

DOI

EISSN

1557-3117

Publication Date

October 2020

Volume

39

Issue

10

Start / End Page

1050 / 1069

Location

United States

Related Subject Headings

  • Surgery
  • Lung Transplantation
  • Immunosuppressive Agents
  • Immunosuppression Therapy
  • Humans
  • Graft Rejection
  • Drugs, Generic
  • Drug Substitution
  • Consensus
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cochrane, A. B., Lyster, H., Lindenfeld, J., Doligalski, C., Baran, D., Yost, C., … Page, R. L. (2020). Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant, 39(10), 1050–1069. https://doi.org/10.1016/j.healun.2020.06.024
Cochrane, Adam B., Haifa Lyster, JoAnn Lindenfeld, Christina Doligalski, David Baran, Colleen Yost, Michael Shullo, et al. “Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.J Heart Lung Transplant 39, no. 10 (October 2020): 1050–69. https://doi.org/10.1016/j.healun.2020.06.024.
Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, et al. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant. 2020 Oct;39(10):1050–69.
Cochrane, Adam B., et al. “Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations.J Heart Lung Transplant, vol. 39, no. 10, Oct. 2020, pp. 1050–69. Pubmed, doi:10.1016/j.healun.2020.06.024.
Cochrane AB, Lyster H, Lindenfeld J, Doligalski C, Baran D, Yost C, Shullo M, Schweiger M, Weill D, Stuckey L, Ivulich S, Scheel J, Peters L, Colvin M, Dawson K, Girgis R, Weeks P, Tse T, Russell S, Flattery M, Jennings D, Kittleson M, Miller T, Khuu T, Claridge T, Uber P, Ford K, Ensor CR, Simpson K, Dipchand A, Page RL. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: Access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant. 2020 Oct;39(10):1050–1069.
Journal cover image

Published In

J Heart Lung Transplant

DOI

EISSN

1557-3117

Publication Date

October 2020

Volume

39

Issue

10

Start / End Page

1050 / 1069

Location

United States

Related Subject Headings

  • Surgery
  • Lung Transplantation
  • Immunosuppressive Agents
  • Immunosuppression Therapy
  • Humans
  • Graft Rejection
  • Drugs, Generic
  • Drug Substitution
  • Consensus
  • 3202 Clinical sciences